Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01000025 · ClinicalTrials.gov registry record · Phase 3
PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer
A Phase 3 study, sponsored by NCIC Clinical Trials Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 720
- Enrollment target
NCT01000025 is a Phase 3 study that has completed, run by NCIC Clinical Trials Group. The registered enrollment target is 720 participants.
The verdict
NCT01000025, a Phase 3 study, has completed, sponsored by NCIC Clinical Trials Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 720 participants
- Enrollment target
Study Summary
RATIONALE: PF-00299804 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether PF-00299804 is more effective than a placebo in treating patients with advanced non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying PF-00299804 to see how well it works compared with a placebo in treating patients with stage IIIB or stage IV non-small cell lung cancer that has not responded to standard therapy for advanced or metastatic cancer.
Interventions
- DRUG Placebo
- DRUG PF-00299804
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 720 participants |
| Start Date | 2009-12-23 |
| Est. Completion | 2015-11-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01000025
The ClinicalTrials.gov registry entry for NCT01000025 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 720 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NCIC Clinical Trials Group, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01000025 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01000025 about?
NCT01000025 is a clinical study titled "PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer". RATIONALE: PF-00299804 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether PF-00299804 is more effective than a placebo in treating patients with advanced non-small cell lung cancer. PURPOSE: This randomized phase III trial is study...
What is the current status of trial NCT01000025?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 720 participants. The study started on 2009-12-23. Estimated completion is 2015-11-27.
What interventions are being tested in trial NCT01000025?
The interventions under investigation include: Placebo (DRUG), PF-00299804 (DRUG).
Who is sponsoring clinical trial NCT01000025?
This trial is sponsored by NCIC Clinical Trials Group, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.